JP2008074719A - Tablet manufacturing method, tablet, and tablet punch - Google Patents

Abstract

[Problem] To provide a tablet production method and a tablet, and a tablet punch that can prevent sticking from occurring when a tablet containing a bioactive ingredient having a low melting point is produced.
The tablet component is tableted using a tableting punch 1 in which at least a part of the surface is coated with titanium carbonitride.
[Selection] Figure 1

Description

  The present invention relates to a method for producing a tablet, a tablet, and a tablet punch, in which the tablet components are tableted using a tablet punch.

  Conventionally, tablets using bioactive ingredients are compressed by adding binders, disintegrants, disintegration aids, excipients, lubricants, organic solvents, etc. to bioactive ingredients or granulated products. Manufactured by molding. In a tablet tablet machine generally used, tablet raw materials are mechanically supplied to a die on a rotating disk by a stirring type feeder, and the tablet raw materials are compressed between an upper punch and a lower punch. A tablet is obtained. At this time, if a crude drug or a physiologically active ingredient having a low melting point is used as a tablet raw material, this raw material adheres to the tip of the tableting punch, and sticking (sticking), which is one of tableting obstacles, occurs. It is known to cause scratches, dullness, irregularities and the like on the surface of the manufactured tablets.

  Conventionally, in order to prevent sticking as described above, a method for improving the sliding between the tip and the composition by increasing the amount of lubricant added, and a composition by increasing the amount of excipient added A method of making the low melting point bioactive ingredient difficult to adhere to the heel, a method of giving the composition a stronger binding force than the binding strength of the heel tip and the composition by increasing the amount of the binder added, When granulating a low-melting-point bioactive component, a method of granulating by blending together a component that does not easily adhere to the low-melting-point bioactive component and an excipient is used.

  However, when the amount of the lubricant added is increased as described above, the tablet may be defective due to a decrease in the binding strength of the composition, or it may be disintegrated due to an increase in the amount of lubricant that is originally hydrophobic. There were problems such as time delay and delayed absorption of physiologically active ingredients. Moreover, when the addition amount of the excipient is increased, the size of the tablet becomes unnecessarily large, and there is a possibility that the user's ease of taking is reduced. In addition, when the amount of the binder added is increased, elution of the physiologically active ingredient from the tablet is remarkably delayed and bioavailability is lowered, which is a serious problem for drugs in which rapid action is important.

  In addition, the method of granulating the physiologically active ingredient together with the excipient requires a large amount of excipient, and when using the dry granulation method, the same adhesion phenomenon as described above occurs. There was a problem that the physiologically active component of this remained on the surface of the granules. In addition, when the wet granulation method is used, there are problems such as processing restrictions when drying a physiologically active component having a low melting point and a decrease in working environment due to the use of an organic solvent.

  As described above, tablets made under the situation where sticking occurs not only have an unfavorable appearance, but also have a serious drawback as a product, such as the uniformity of the coating film being impaired when the tablets are coated. Because it is connected, a fundamental solution to sticking is desired.

In order to solve the above problems, for example, a method of blending a crystalline powder having an average particle diameter of 1 to 100 μm with an active ingredient having a low melting point has been proposed (for example, Patent Document 1).
Further, a method of adding a tableting aid containing crystalline cellulose, light anhydrous silicic acid or the like to a granulated product containing ibuprofen (low melting point active ingredient) has been proposed (for example, Patent Document 2).
However, both of Patent Documents 1 and 2 are methods of adding a modifier, which may lead to an increase in the amount of tablets, and the mixing properties of tableting powder may be reduced.

  In addition, since the obstacle in tableting is caused by the melting point drop between the components, a plurality of components causing the melting point drop are mixed and mixed, or the granules granulated at a temperature at which these multiple components do not melt. A method of blending has been proposed (for example, Patent Document 3). However, the method described in Patent Document 3 has a problem that the manufacturing process of tableting powder becomes complicated.

Moreover, as a countermeasure in terms of an apparatus used for tableting, an apparatus using a so-called external lubrication method in which a lubricant is applied only to the tablet surface has been proposed (for example, Patent Documents 4 and 5). However, the methods described in Patent Documents 4 and 5 require a special device, and thus have a problem of poor versatility.
JP-A-10-59842 Japanese Patent Laid-Open No. 9-143065 JP 2001-31650 A JP 2001-104453 A Special Table 2000-19983

As described above, tablets that are generally produced are tableted by compressing the tableting powder using a punch and a mortar provided in the tableting machine. For example, a mortar hole is formed in the mortar attached to the rotating disk, the position of the lower armpit arranged below the mortar hole is adjusted, the space in the mortar hole is set to a predetermined volume, and the powder in the mortar hole A tablet is formed by storing a tableting powder such as a medicine and compressing it with an upper punch, and thereafter, the tablet is pushed up with a lower punch and taken out from the mortar.
The tableting punch as described above is required to have high mechanical strength so as not to be easily deformed by a frequently repeated compression operation, and conventionally, super steel alloys and alloy tool steels are used, As a countermeasure against corrosion, a chrome-plated surface is used.

  In conventional tableting punches using alloy tool steel or the like, the metal material has such a property that the tableting powder adheres to the surface. Therefore, in particular, a pharmacological agent or excipient (for example, When tableting powder containing an adhesive substance such as sugar alcohol) is tableted, adhesion to the tableting punch becomes more prominent. If the tableting powder adheres to the tableting punch, the releasability between the tableting powder and the surface of the tablet will be reduced, and the tableted tablet surface will become rough or the tablet surface will be clearly marked. There is a risk that it cannot be formed. For this reason, when manufacturing a tablet using the component containing adhesive substances, such as a pharmacological agent and an excipient | filler, the suitable manufacturing method which does not produce the above problems was desired.

  The present invention has been made in view of the above problems, and provides a tablet manufacturing method, a tablet, and a tablet punch that can prevent sticking when manufacturing a tablet containing a bioactive component having a low melting point. The purpose is to do.

The inventors of the present invention have intensively studied to solve the above problems. As a result, when manufacturing tablets containing a crude drug or a physiologically active component having a low melting point of 70 to 150 ° C., tableting coated with titanium carbonitride is performed. It has been found that by tableting with a punch, even if tableting is continued for a long time, adhesion of the composition to the tip of the punch (sticking) is prevented and stable tableting can be continued. Completed the invention.
That is, the present invention relates to the following.

That is, the tablet production method of the present invention is characterized in that the tablet components are tableted using a tableting punch whose surface is coated with titanium carbonitride.
Moreover, the manufacturing method of the tablet of this invention can make the said tablet component the structure containing 1 type, or 2 or more types chosen from the group of the bioactive component which has 70-150 degreeC melting | fusing point.
Further, in the method for producing a tablet of the present invention, the physiologically active ingredient is aspirin, ibuprofen, phenacetin, flufenamic acid, etenzamide, salicylamide: sazapyrine, aminopyrine, antipyrine, isopropylantipyrine, clofesone, ketophenylbutazone, phenylbuta It can be set as the structure which consists of 1 type (s) or 2 or more types chosen from the group of Zon, Alclofenac, vitamin A, vitamin D2, vitamin D3, vitamin D4.
Moreover, the manufacturing method of the tablet of this invention can be set as the structure in which the said tablet component contains a crude drug extract powder, a living microbe, or the particle | grains containing them.
The tablet of the present invention is obtained by each of the above production methods.
The tableting punch of the present invention is a tableting punch that compresses tablet components into tablets, and is characterized in that at least a part of the surface is coated with titanium carbonitride.

According to the tablet manufacturing method of the present invention, since tablet components are tableted using a tableting punch having at least a part of the surface coated with titanium carbonitride, a low melting point physiologically active component is tableted. Even so, it is possible to prevent the low melting point bioactive component from adhering to the tableting punch of the tableting machine. Thereby, even if the tableting is performed for a long time and the temperature of the tableting punch rises, the tablet can be tableted stably and stably without impairing the quality of the tablet. it can.
Therefore, tablets with excellent quality can be obtained with high production efficiency, and improvement in quality and reduction in production cost can be realized with a simple configuration.

  Hereinafter, an embodiment of a tablet manufacturing method, a tablet, and a tableting punch according to the present invention will be described with reference to FIG. 1 as appropriate.

  The tablet production method of the present embodiment is a method of tableting tablet components using a tableting punch having at least a part of the surface coated with titanium carbonitride.

[tablet]
As described above, the tablet of this embodiment is obtained by tableting the tablet component (tablet composition) with a tableting punch having at least a part of the surface coated with titanium carbonitride.
Hereinafter, the tablet of this embodiment will be described in detail.

  The tablet component of this embodiment contains a physiologically active component having a low melting point of 150 ° C. or lower, preferably 70 to 150 ° C. Such a physiologically active component having a low melting point is not particularly limited as long as the melting point is in the above range, and any component may be used. Specifically, the following physiologically active ingredients can be mentioned as representative examples, but are not limited thereto. For example, phenacetin: 134 to 137 ° C. (melting point, the same applies hereinafter), flufenamic acid: 134 ° C., aspirin: 136 ° C, ethenamide: 131-134 ° C, salicylamide: 104 ° C, sazapyrine: 136-145 ° C, aminopyrine: 107-109 ° C, antipyrine: 111-113 ° C, isopropylantipyrine: 103-105 ° C, clofezone: 94.5 ~ 97.5 ° C, ketophenylbutazone: 126-129 ° C, phenylbutazone: 104-107 ° C, alclofenac: 91-94 ° C, ibuprofen: 75-77 ° C, vitamin A: 62-64 ° C, vitamin D2: 115-118 ° C, vitamin D3: 84-85 ° C, vitamin D4 108 ° C., and the like.

  Glucuronolactone: 170 to 174 ° C., sucralfate, vitamins (B1: 248 ° C., B2: 280 ° C., B6: 160 ° C., A: 62-64 ° C., C: 190-192 ° C., D2: 115-118 C., D3: 84 to 85.degree. C., D4: 108.degree. C., H: 232.degree.

  Further, methylmethionine, sulfonium, chloride: 140 ° C., cimetidine: 140-145 ° C., ranitidine hydrochloride: 140 ° C., famotidine: 164 ° C., loxatidine acetate hydrochloride: 147-151 ° C., sofalcone: 142-146, apple Examples include gastrointestinal drug-related components such as acid cleboprid: 160 to 165 ° C., spizofuron: 105 to 108 ° C., trimebutine maleate: 131 to 135 ° C., and the like.

  In addition, dextromethorphan hydrobromide: 126 ° C, noscapine: 174-177 ° C, acetylcysteine: 107 ° C, guaifenesin: 79-83 ° C, diprofylline: 159-163 ° C, epinephrine hydrochloride: 157-160 ° C, Antitussive expectorant-related ingredients such as codeine phosphate, dihydrocodeine phosphate, and the like.

  Further, antipruritic-related components such as dimenhydrinate: 102 to 107 ° C., betahistine mesylate: 110 to 114 ° C., bromvalenyl urea: 151 to 155 ° C., glutethimide: 83 to 88 ° C., flurazepam: 79 to 83 Also included are hypnotic / sedative-related ingredients such as ° C.

In addition, herbal extract powder having a melting point of 150 ° C. or less, viable bacteria such as lactic acid bacteria, or granulated particles containing them can be used. As herbal extracts, for example, funnel extract, peony extract, red mulberry extract, etc. Is mentioned.

  The above-mentioned physiologically active components having a low melting point can be used singly or in combination of two or more, and in particular 1 selected from the group of aspirin, etenzaamide, alclofenac, and ibuprofen. The effect is remarkable in a seed or a combination of two or more.

  In the tablet component of the present embodiment, the blending amount of the physiologically active component having a low melting point is not particularly limited and can be appropriately adjusted depending on the intended use of the tablet to be prepared. It is -99 weight%, Preferably it is 5-90 weight%, More preferably, it is 10-80 weight%.

In addition, the blending mode of the low melting point physiologically active ingredient is not particularly limited, and for example, the method of blending as it is, the method of granulating according to the usual method such as the dry method or the wet method, or the fatty acid, glycerin Or these derivatives, organic compounds such as crystalline polymers (water-soluble, water-insoluble, enteric, gastric, etc.), or silicates, carbonates, oxides, hydroxides which are 1 to 3 metal salts It is possible to use a method of coating with an inorganic compound such as a product or using a surface-modified one.
Moreover, as a diameter of the granulated material in this case, it is preferable to use those having an average particle diameter of 1000 μm or less, particularly 850 to 50 μm. If the average particle size of the granulated product exceeds 1000 μm, the content may be uneven or not suitable for tableting.

The tablet of the present embodiment may be anything as long as it has a so-called tablet shape, and may be a fine particle containing a drug, a tablet containing a pellet, or the like.
Also, when manufacturing such tablets, the above-mentioned physiologically active ingredients (drugs) are usually mixed with excipients, lubricants, disintegrants, etc. to form tableted powders, which are compressed with a pestle and a mortar. By doing so, it can be formed as a tablet. Furthermore, the tablet obtained in this way may be surface-coated according to a conventional method to give a product. If necessary, preparation additives such as preservatives, antioxidants, coloring agents, sweeteners, fragrances, flavors and the like can be blended into the tableting powder to produce tablets.

Suitable examples of the excipient used in the present embodiment as described above include, for example, sugars such as lactose and sucrose, sugar alcohols such as D-mannitol and D-sorbitol, starch (for example, corn starch, potato starch) , Wheat starch, etc.), pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, gum arabic, dextrin, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, carboxymethylcellulose calcium, aluminum metasilicate Examples include magnesium acid.
In addition, the content of these excipients in the tablet is preferably in the range of 10 to 80% by mass, and more preferably in the range of 20 to 60%. If the content of the excipient is within this range, tableting becomes easy.

Moreover, as a suitable example of the lubricant used by this embodiment, a magnesium stearate, a calcium stearate, a talc, colloidal silica etc. are mentioned, for example.
Moreover, it is preferable that content in the tablet of these lubricants is the range of 0.01-5 mass%. If the content of the lubricant is less than 0.01% by mass, the sticking suppression effect may not be sufficient, and if it exceeds 5% by mass, poor tableting due to a decrease in binding force and hydrophobicity increase. The decay delay due to this is likely to occur.

Moreover, as a suitable example of the binder used in this embodiment, for example, starch, pregelatinized starch, sucrose, gelatin, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D-mannitol , Trehalose, dextrin, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like.
Moreover, it is preferable that content in the tablet of these binders is the range of 0.5-10 mass%. If the content of the binder is within this range, the moldability at the time of tableting can be maintained without impairing the disintegration property of the tablet.

Moreover, as a suitable example of the disintegrating agent used in the present embodiment, for example, starch, pregelatinized starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, crospovidone, light anhydrous silicic acid, Examples include low-substituted hydroxypropylcellulose.
In addition, the content of these disintegrants in the tablet is preferably in the range of 0.5 to 30% by mass, and more preferably in the range of 1 to 20%. If the content of the disintegrant is within this range, a tablet having an appropriate disintegration property can be obtained without impairing the moldability during tableting.

  Examples of the coating agent used on the surface of the tablet include hydroxypropylmethylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, polyoxyethylene glycol, Tween 80, Pluronic F68, castor oil, cellulose acetate phthalate, hydroxymethylcellulose acetate succin Nate, Eudrakit (acrylic acid copolymer: manufactured by Rohm; Germany), carboxymethylethylcellulose, porvinylacetal diethylaminoacetate, waxes and pigments such as talc, titanium oxide, and bengara.

  Examples of the acidulant added to the tablet component include citric acid (anhydrous citric acid), tartaric acid, malic acid and the like. Examples of the artificial sweetener include saccharin sodium, glycyrrhizin dipotassium, aspartame, stevia, thaumatin and the like. Moreover, as a fragrance | flavor, any of a synthetic material and a natural product may be sufficient, for example, lemon, lime, orange, menthol, strawberry, etc. are mentioned. Examples of the colorant include food dyes such as food yellow No. 5, food red No. 2, food blue No. 2, etc., food lake dyes, bengara, talc, tar dyes, and the like.

[Tablet punch]
The tableting punch of this embodiment is formed by coating at least a part of the surface with titanium carbonitride. The tableting punch 1 provided in the tableting machine 20 illustrated in FIG. 1 is configured such that the entire surface 10a, 11a of the upper punch 10 and the lower punch 11 is coated with titanium carbonitride.

  As a base material for a tableting punch, it is preferable to use a material that is not easily deformed and has excellent mechanical strength, such as cemented carbide, alloy tool steel, punching metal, etc. Specific examples include SKD, SKH, and austenitic SUS. Among these, SKD is most preferable.

In the tableting punch of the present embodiment, for the titanium carbonitride coating treatment on the surface of the base material, a conventionally known method, for example, CVD that gasifies component elements into molecules and forms a film by a chemical reaction. Or a PVD ion plating method in which a gaseous element is ionized by decomposing with a plasma to form a film.
In addition, the coating treatment with titanium carbonitride applied to the surface of the base material may be a single layer coating with titanium carbonitride, but for example, a multi-layer coating in which titanium nitride and titanium carbide are multilayered is applied. It is more preferable in that it can reliably prevent the low melting point physiologically active ingredient from adhering to the tablet bag.

The tableting punch of this embodiment preferably has a coating thickness on the surface of the base material in the range of 1 to 10 μm.
By setting the thickness of the coating within the above range, it is possible to reliably prevent the bioactive component having a low melting point from adhering to the surface of the tablet punch.

  The tableting punch of this embodiment can also be made of titanium carbonitride as the base material. In this case, the tableting punch can be used for tableting without any particular coating treatment. it can.

  Moreover, the tableting punch 1 provided in the tableting machine 20 illustrated in FIG. 1 is configured such that the entire surface 10a, 11a of the upper punch 10 and the lower punch 11 is coated with titanium carbonitride. However, it is not limited to this. For example, if only at least the tip portions 10b and 11b of the tableting punch 1 (the upper punch 10 and the lower punch 11) are coated with titanium carbonitride, the upper punch 10 and the lower punch 11 as described above. It is possible to reliably prevent the bioactive component having a low melting point from adhering to the surface.

  A tableting machine that performs tableting using the tableting punch of the present embodiment to produce a tablet is not particularly limited. For example, a rotary tableting having a cross-sectional structure as shown in FIG. A known tableting machine such as a machine can be used.

A tableting machine 20 provided with the tableting punch of the present embodiment illustrated in FIG. 1 has a predetermined distance in the circumferential direction of the tableting punch 1 composed of an upper punch 10 and a lower punch 11 and a disk-shaped rotating disk 3. A plurality of tablet mills 2 are provided, and an upper punch 10 is held on the upper punch holding plate 4 so as to be movable up and down with respect to the tablet mill 2 above the tablet mill 2. A lower punch 11 is held on the lower punch holding plate 5 so as to be movable up and down, and the tip of the lower punch 11 is placed in the locking mill 2 below the locking mill 2. It is rushed from below.
Although not shown in detail, the rotary plate 3, the upper platen holding plate 4 and the lower platen holding plate 5 are formed in a disc shape and are driven to rotate coaxially. These are guided by guide rails (not shown) and driven up and down at predetermined positions.
Further, the upper collar 10 and the lower collar 11 are each coated with titanium carbonitride on the entire surfaces 10a and 11a.

Below, the procedure at the time of manufacturing a tablet with the tableting machine 20 provided with the punch 1 for tableting of this embodiment is demonstrated.
First, the lower punch 11 is positioned at a predetermined height by a guide rail (not shown), the space in the tablet making die 2 is set to a predetermined volume, and the tabletting powder in the table making die 2 is filled in the tablet making powder filling zone. 30 is filled.
Next, in the tableting end compression zone, the upper punch 10 is guided by a guide rail (not shown), moved downward, guided to the compression roller, and compressed by compressing the tableting end 30.
Next, the upper punch 10 is guided by a guide rail (not shown) and lifted upward, and the lower punch 11 is pushed upward by the guide rail (not shown) in the tablet takeout zone. The compression-molded tablet is taken out.

In the tablet production method of the present embodiment, the tablet composition as described above can be tableted under a conventionally known condition using a tableting machine equipped with the tableting punch as described above. Thereby, a tablet having a diameter of about 3 to 12 mm and a thickness (center portion) of about 1 to 10 mm can be stably obtained. And even when the tableting pressure by the tableting machine is about 0.1 to 4 t continuously, it is possible to prevent sticking from occurring in the tableting punch and to perform tableting stably. Become.
In addition, the tablet obtained with the manufacturing method of this embodiment can also be made into various deformation tablets other than a circular tablet, and a shape in particular is not limited.

As described above, according to the tablet manufacturing method of the present embodiment, since the tablet components are compressed using a tableting punch having at least a part of the surface coated with titanium carbonitride, the low melting point is reduced. Even when the physiologically active ingredient is tableted, the low melting point physiologically active ingredient can be prevented from adhering to the tableting punch of the tableting machine. Thereby, even if the tableting is performed for a long time and the temperature of the tableting punch rises, the tablet can be tableted stably and stably without impairing the quality of the tablet. it can. Therefore, tablets with excellent quality can be obtained with high production efficiency, and improvement in quality and reduction in production cost can be realized with a simple configuration.
The production method of the present embodiment has a great effect of preventing the low-melting-point physiologically active ingredient from adhering to the tableting punch, particularly when tableting for a long time.

  Hereinafter, examples for demonstrating the tablet production method and tablet of the present invention and the punch for tableting will be described, but the present invention is not limited to this example.

[Tablet punch]
In this example, a tablet made of SKD-11 (JIS G 4404: 2006) was used as a tableting punch.
In addition, the surface of the tablet punch was coated with three types of coatings, ie, titanium carbonitride coating, hard chromium plating, and chromium nitride coating, and the entire surface of the punch was coated. The surface of the tablet punch was coated by titanium carbonitride coating: CVD method, chromium nitride coating: PVD method, and the thickness of the coating layer was 2 to 5 μm.

[Tablet ingredients]
In the present Example, the tablet which has a tablet composition as shown to the following compositions 1-3 was manufactured.
And the tablet manufactured on each condition was evaluated using each punch for tableting with which said 3 types of coating was given.

<Composition 1>
Using ibuprofen as a physiologically active substance having a low melting point, a tablet having the composition shown in the following (1) was produced by the method shown in the following (2).
(1) Composition a: ibuprofen: 800 parts by weight b: corn starch: 150 parts by weight c: hydroxypropylcellulose: 50 parts by weight d: anhydrous caffeine: 400 parts by weight e: crystalline cellulose: 400 parts by weight f: mannitol: 160 parts by weight Part g: Magnesium stearate: 40 parts by weight

(2) Method Using a fluidized bed granulator, a solution in which 200 g of hydroxypropylcellulose was previously dissolved in water was sprayed at a temperature of 65 ° C. with a solution of 2400 g of ibuprofen and 450 g of corn starch added to 4000 g. Grained. After drying this, the particle size was adjusted by passing through a sieve having an opening of 850 μm.
Next, 400 g of anhydrous caffeine, 400 g of crystalline cellulose, and 160 g of mannitol were added to 1000 g of the obtained granulated product, and mixed for 15 minutes using a V-type mixer (manufactured by Tokuju Kakujo Co., Ltd.). Furthermore, 40 g of magnesium stearate was added and mixed for 5 minutes to obtain a tablet composition.
Using the tableting machine (LIBRA: manufactured by Kikusui Seisakusho Co., Ltd.) provided with a plurality of tableting punches on a rotating disk, the resulting composition was tableted with a diameter of 8 mm and a tip radius of 12 mm. Tableting was carried out using a punch for tableting with a tableting pressure of 1.0 t.

<Composition 2>
Using aspirin as a physiologically active substance having a low melting point, a tablet having the composition shown in the following (1) was produced by the method shown in the following (2).
(1) Composition a: aspirin: 500 parts by weight b: anhydrous caffeine: 120 parts by weight c: hydroxypropyl starch: 80 parts by weight d: crystalline cellulose: 150 parts by weight e: lactose: 200 parts by weight f: magnesium stearate: 30 parts by weight

(2) Method After mixing 17500 g of aspirin and 2800 g of hydroxypropyl starch for 5 minutes using a V-type mixer (manufactured by Tokuju Kogyo Co., Ltd.), the mixture is granulated using a dry granulator. After the granulation, granules having an average particle size of 230 μm were obtained.
Next, 1200 g of anhydrous caffeine, 1500 g of crystalline cellulose, and 2000 g of lactose were added to 5800 g of the obtained granules, and mixed for 15 minutes using a V-type mixer. Furthermore, 300 g of magnesium stearate was added and mixed for 5 minutes to obtain a tablet composition.
The obtained composition was tableted using a tableting machine (LIBRA: manufactured by Kikusui Seisakusho Co., Ltd.) provided with a plurality of tableting punches on a rotating disk, and having a diameter of 10 mm and a tip radius of 8 mm. Tableting was carried out using a punch for tableting with a tableting pressure of 1.5 t.

<Composition 3>
Using aspirin as a physiologically active substance having a low melting point, a tablet having the composition shown in the following (1) was produced by the method shown in the following (2).
(1) Composition a: First layer: aspirin: 80 parts by weight
... Corn starch: 20 parts by weight b: Second layer ... Magnesium carbonate: 120 parts by weight
... Corn starch: 30 parts by weight

(2) Method First, for the first layer, 16,000 g of aspirin and 4000 g of corn starch were mixed for 5 minutes using a V-type mixer (manufactured by Tokuju Factory) and then granulated using a dry granulator. And after granulating this, the granule whose average particle diameter is 500 micrometers was obtained.
For the second layer, first, 1500 g of corn starch was dissolved by heating in water so as to be 8% by weight. Next, 12,000 g of magnesium carbonate and 1500 g of corn starch were added to this corn starch solution, and granulated by spraying an aqueous corn starch solution while stirring with heating using a stirring granulator. After spraying, the granulated product was dried using a fluidized bed granulator, and after granulating this, granules having an average particle size of 300 μm were obtained.
The granules of the first layer and the second layer obtained as described above are respectively obtained from a tableting machine (LIBRA: manufactured by Kikusui Seisakusho) in which a plurality of tableting punches are provided on a rotating disk. The tablet was put into a mortar having a diameter of 10 mm and tableted with a tableting punch having a tip radius of 8 mm at a tableting pressure of 1.2 t to produce a two-layer tablet.

[Evaluation methods]
The tableting powder composed of the components of the above compositions 1 to 3 is subjected to continuous tableting for 2 hours under the conditions shown in the following examples and comparative examples, and tableting at each time point of 30 minutes, 1 hour, and 2 hours. The surface of the punch (tablet portion) and the surface of the manufactured tablet were observed and evaluated according to the following criteria.
<Evaluation of surface of punch for punch>
(1) ○: Adhesion of the tableting powder (sticking) was not observed on the tableting punch.
(2) Δ: Adherence of the tableting powder was observed on a part of the tableting punch.
(3) X: Adhesion of tableting powder was observed on all tableting punches.
<Evaluation of tablet surface>
(1) ○: Dullness or irregularities were not seen on the surface of the tablet, and it was beautiful.
(2) x: A rough surface portion due to dullness or unevenness was observed on the surface of the tablet.

[Example 1, Comparative Examples 1-2]
Tablets were produced by the composition and method shown in the above composition 1. At this time, Example 1 was coated with carbonitride, Comparative Example 1 was hard chrome plated, and Comparative Example 2 was coated with chromium nitride.

[Example 2, Comparative Examples 3 to 4]
Tablets were produced by the composition and method shown in Composition 2 above. At this time, the surface of the tablet punch was coated with carbonitride coating in Example 2, hard chrome plating in Comparative Example 3, and chromium nitride coating in Comparative Example 4.

[Example 3, Comparative Examples 5 to 6]
Tablets were produced by the composition and method shown in Composition 3 above. In this case, the surface of the tablet punch was coated with carbonitride coating in Example 3, hard chrome plating in Comparative Example 5, and chromium nitride coating in Comparative Example 6.

  Table 1 shows the evaluation results of the tablets produced in Examples 1 to 3 and Comparative Examples 1 to 6.

[Evaluation results]
As shown in Table 1, in Examples 1 to 3 in which tablets were produced using the method for producing tablets according to the present invention, the surface of the tableting punch was carbonitrided, so 30 minutes to 2 hours Even when continuous tableting was performed, all the evaluation results of the surface of the tableting punch were ◯, and it was confirmed that the tableting powder (tablet component) did not adhere to the punches at all.
In addition, the tablets obtained in Examples 1 to 3 all had a surface evaluation result of ◯, and no dullness or unevenness was observed on the surface of the tablet, and it was confirmed that the tablets were good surfaces.

  On the other hand, in Comparative Examples 1, 3, and 5 in which the surface of the tableting punch was hard chrome-plated, the tableting powder adhered to the surface of the tableting punch when 30-minute continuous tableting was performed. However, after 2 hours of continuous tableting, adhesion of the tableting powder to the surface of a part of the tableting punch was confirmed, and the evaluation result of the surface of the tableting punch was Δ. Accordingly, in Comparative Examples 1, 3, and 5, the tablets obtained after continuous tableting for 2 hours were confirmed to have rough surfaces on the surface, and the evaluation results of the surfaces were all x.

  Further, in Comparative Example 2 in which the surface of the tableting punch was coated with chromium nitride, the tableting powder did not adhere to the surface of the tableting punch when the tableting was continued for 30 minutes. After continuous tableting for 2 hours, it was confirmed that the tableting powder adhered to the surface of a part of the tableting punch, and the evaluation result of the surface of the tableting punch was Δ. Similarly, Comparative Examples 4 and 6 in which the surface of the tableting punch was coated with chromium nitride and tableting powder containing aspirin as a physiologically active substance was tableted at the time of continuous tableting for 30 minutes. Then, although only a part of the tableting powder adhered to the surface of the tableting punch, after 2 hours of continuous tableting, it was confirmed that the tableting powder adhered to all of the tableting punches. As a result, the evaluation result of the surface of the tableting punch was x. In addition, with the attachment of the tableting powder to these tableting punches, the tablets obtained in Comparative Examples 2, 4, and 6 were confirmed to have rough surfaces on the surface, and the evaluation results of the surfaces were all x. .

  From the above results, the low-melting-point bioactive ingredient adheres to the tableting punch of the tableting machine even when the tablet manufacturing method according to the present invention tablets the low-melting-point bioactive ingredient. Therefore, even if the tableting is performed for a long time and the temperature of the tableting punch rises, the tablet can be tableted stably and stably without deteriorating the quality of the tablet. It became clear.

It is the schematic explaining an example of the manufacturing method of the tablet which concerns on this invention, and is a figure which shows the cross section of the tableting machine provided with the punch for tableting.

Explanation of symbols

DESCRIPTION OF SYMBOLS 1 ... Tableting punch, 2 ... Tableting mill, 3 ... Rotating board, 4 ... Upper punch holding board, 5 ... Lower punch holding board, 10 ... Upper punch (tablet punch), 11 ... Lower punch (tablet) Note) 10a, 11a ... surface, 30 ... tablet powder (tablet component)

Claims (6)

  A method for producing a tablet, wherein the tablet component is tableted using a tableting punch having at least a part of the surface coated with titanium carbonitride.   The said tablet component contains 1 type, or 2 or more types chosen from the group of the bioactive component which has 70-150 degreeC melting | fusing point, The manufacturing method of the tablet of Claim 1 characterized by the above-mentioned.   The physiologically active ingredient is aspirin, ibuprofen, phenacetin, flufenamic acid, etenzamide, salicylamide :, sazapyrine, aminopyrine, antipyrine, isopropylantipyrine, clofesone, ketophenylbutazone, phenylbutazone, alclofenac, vitamin A, vitamin D2 It consists of 1 type, or 2 or more types chosen from the group of vitamin D3 and vitamin D4, The manufacturing method of the tablet of Claim 2 characterized by the above-mentioned.   The tablet manufacturing method according to claim 1, wherein the tablet component contains crude drug extract powder, live bacteria, or particles containing them.   The tablet obtained by the manufacturing method of Claims 1-4. A tableting punch for tableting tablet components, wherein at least a part of the surface is coated with titanium carbonitride.

Images